Menu
Search
|

Menu

Close
X

Urogen Pharma Ltd URGN.OQ (NASDAQ Stock Exchange Global Market)

47.92 USD
-2.16 (-4.31%)
As of Feb 16
chart
Previous Close 50.08
Open 49.86
Volume 57,543
3m Avg Volume 48,582
Today’s High 50.03
Today’s Low 46.81
52 Week High 56.43
52 Week Low 13.01
Shares Outstanding (mil) 13.01
Market Capitalization (mil) 381.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
8
FY16
18
FY15
0
EPS (USD)
FY17
-0.720
FY16
-6.122
FY15
-0.874
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
5.16
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Arie Belldegrun
Chairman of the Board, Since 2012
Salary: --
Bonus: --
Ron Bentsur
Chief Executive Officer, Director, Since 2015
Salary: --
Bonus: --
Gary Titus
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Gil Hakim
President - Israeli Operation, Since 2015
Salary: --
Bonus: --
Chaim Hurvitz
Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

9 Ha'Ta'asiya St
RA'ANANA     4365007

Phone: +9729.7707601

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

SPONSORED STORIES